LYTIR

Company · ADRX

ADARx Pharmaceuticals, Inc.

Nasdaq's symbol directory lists ADRX on Nasdaq as “ADARx Pharmaceuticals, Inc. - Common stock”.

In the 12 months to Nov 19, 2026: insiders bought on 2 occasions ($43.4M); 6 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 15, No. 14, No. 13, No. 12, No. 11, No. 10, No. 9, No. 8

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Simeon George bought on 1 day latest Sep 28, 2026 bought $27.2M
  2. ORBIMED ADVISORS LLC bought on 1 day latest Sep 28, 2026 bought $16.1M
Every trade (2)
  1. BUYSimeon George bought Sep 28, 2026 1,600,000 shares 3 legs combined filing $27.2M
  2. BUYORBIMED ADVISORS LLC bought Sep 28, 2026 950,000 shares 3 legs combined filing $16.1M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Zhen Li filed Nov 16, 2026 Schedule 13G/A passive filing 9.6%
  2. Zhen Li filed Nov 13, 2026 Schedule 13G passive filing 9.7%
  3. LAV Biosciences Fund V, L.P. filed Oct 16, 2026 Schedule 13G passive filing 11.1%
  4. SR One Capital Management, LLC filed Oct 5, 2026 Schedule 13D may seek influence 9,936,661 shares filing 9.3%
  5. ORBIMED ADVISORS LLC filed Oct 2, 2026 Schedule 13D may seek influence 14,913,764 shares filing 14%
  6. BCLS Fund III Investments, LP filed Oct 1, 2026 Schedule 13G passive filing 6.3%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition; Regulation FD disclosure filing Nov 12, 2026
  2. Unregistered sales of equity securities; Amendments to articles or bylaws; change in fiscal year; Other events filing Sep 28, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.